Clinical Trial Update: TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating TB-500 (Thymosin Beta-4 17-23 fragment) for cardiovascular biomarkers in stable atherosclerotic cardiovascular disease.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Endothelial Dysfunction

Drugs mentioned

• TB-500 (Thymosin beta-4 fragment (17-23))

Snippet

Sponsor: Hudson Biotech | Conditions: Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1, Phase 2 | Status: RECRUITING